More Clinical Articles


Automation is key in cell and gene therapy manufacturing

Andrew Stone, (Oct 30, 2020)

Although the list of cell and gene therapies is growing, prices remain high. Now developers are working on a road map to streamline production and drop costs
Patients and Medical

From complexity to clarity in cell and gene therapy

Andrew Stone, (Sep 16, 2020)

Breakthrough CGT therapies are coming thick and fast, now pharma must work on multiple fronts to educate non-specialist stakeholders about their exciting possibilities
Access and Evidence

Survey results: Accelerating digital transformation during COVID-19

Nicola Davies, (Sep 4, 2020)

View the results of a survey of over 1000 pharma executives on the impact COVID-19 has had and will have on their operations

Breaking new ground in healthcare data

Andrew Stone, (Apr 16, 2020)

Pharma should team up with HCPs, regulators and health ministries to create harmonised, interoperable health records and so drive cheaper, faster insights
Patients and Medical

Building a bridge to a COVID-19 vaccine

Andrew Stone, (Apr 15, 2020)

Regeneron shares its latest progress on therapies for the pandemic at eyeforpharma Philadelphia virtual

Moving remote: the post-pandemic clinical trial

Lucy Fulford, (Apr 3, 2020)

Pharma is rapidly adapting its approach to trials in the face of the pandemic and there is great opportunity for far reaching improvements once this is all over

Imagining the ‘Digitome’

Andrew Stone, (Feb 28, 2020)

Dramatic advances in human health beckon if pharma can help build ‘the Digitome’, a vast data commons

RWE: A new hope for rare disease

Lucy Fulford, (Jan 30, 2020)

RWE shows great promise in helping accelerate treatments for rare disease
Access and Evidence

Into pharma's roaring twenties

Paul Simms, (Jan 14, 2020)

A new decade is here. And despite the incredible science, pharma is ill-equipped.

Telemedicine: The future of clinical trials?

Nicola Davies, (Dec 13, 2019)

There is a new surge of interest in telemedicine’s potential to optimize clinical trials, but is this what patients want?